表紙
市場調查報告書

口腔乾燥症治療藥市場 - 成長,趨勢,及預測(2019年 - 2024年)

Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 871437
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
價格
Back to Top
口腔乾燥症治療藥市場 - 成長,趨勢,及預測(2019年 - 2024年) Xerostomia (Dry Mouth Disease) Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 117 Pages
簡介

本報告提供全球口腔乾燥症治療藥市場的相關調查,市場概況和成長要素、阻礙因素,各產品類型、通路、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人口的增加
    • 癌症治療的化療及放射線治療選擇的增加
    • 乾燥症(修格蘭氏症候群),HIV,糖尿病,阿茲海默症,及其他疾病的罹患率增加
  • 市場阻礙因素
    • 新興國家的口腔乾燥症的認識缺乏
    • 有效的治療方法的不可利用
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業的競爭

第5章 市場區隔

  • 各產品類型
    • 人工唾液
    • 唾液刺激物
    • 唾液替代
    • 治療藥
    • 唾液筆
    • 其他
  • 各銷售管道
    • 院內藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Acacia Pharma
    • Church & Dwight Co. Inc.
    • GlaxoSmithKline PLC
    • Hikma Pharmaceuticals PLC
    • Lupin
    • OraCoat
    • Parnell Pharmaceuticals Inc.
    • Pendopharm
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Synedgen

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64759

Market Overview

Factors such as the increase in radiation therapy and chemotherapy would lead to an increased incidence of xerostomia, acting as a major driver for the xerostomia therapeutics market. Other factors driving the market growth are increasing usage of prescription medicines, easy availability and cost-effectiveness of medicines, rising geriatric population base and increasing prevalence of diseases, such as Sjogren's syndrome, HIV, diabetes, Alzheimer's disease, and other diseases. Further, lack of awareness, unavailability of effective treatment may hinder the usage of xerostomia therapeutics products and can act as a restraining factor for the xerostomia therapeutics market.

Scope of the Report

Xerostomia is defined as dry mouth, resulting from reduced or absent saliva flow. It is not a disease, but it could be a symptom of various medical conditions, a side effect of radiation to the head and neck, or a side effect caused by a wide variety of medications. It may or may not be associated with the decreased salivary gland function. Xerostomia is a common complaint found often among older adults, affecting approximately 20% of the elderly.

Key Market Trends

Artificial Saliva Segment dominates the Market

The reduction of saliva in the mouth can lead to tooth decay, mouth infections, an altered sense of taste or smell, difficulty swallowing, pain, and many other complications. Artificial saliva is a liquid or aerosol products that are sprayed into the mouth. They are designed to moisten and relieve the pain and discomfort from chronic dry mouth, especially with regular use. While researchers are not currently able to perfectly replicate the complex chemical and physical structure of natural saliva, artificial saliva products typically do contain buffering agents, cellulose derivatives, and other elements that help temporarily promote moisture. While many artificial saliva sprays and gels claim to work for up to two hours, many users require more frequent applications to maintain moisture in the mouth, which can greatly interfere with a good night's sleep and daily activity. This also results in a greater financial expense compared to more cost-effective alternatives. Many saliva sprays and gels also have a reputation for strong and unpleasant flavors, though a recent increase in the use of naturally sweet xylitol has led to more tasteful alternatives. However, due to the increasing disease prevalence, availability of over-the-counter artificial saliva products, and the ease of application of artificial saliva, the segment is expected to register steady growth during the forecast period.

Asia Pacific Region is the Fastest Growing Region

Asia Pacific is expected to grow with a lucrative CAGR over the forecast period due to growing healthcare expenditure, increase in initiatives for raising awareness, and rising prevalence of diseases such as diabetes, HIV, cancer, & Parkinson's disease that cause dry mouth conditions. Cancer rates are increasing drastically in Asia Pacific region, with rising incomes and better access to childhood vaccinations people are living longer, which is leading to longer exposure to behavioral risk factors and the latter may lead to cancer. Emerging economies such as China and India have adopted both health and industrial policy for encouraging domestic production of cancer drugs, which is leading to lower therapy costs. Lower therapy costs, coupled with increasing awareness about cancer, and is leading to higher adoption of chemotherapy and radiotherapy.

Competitive Landscape

Key players in Xerostomia (Dry Mouth Disease) Therapeutics Market are focusing on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. Some of the key players dominating the xerostomia therapeutics market are Acacia Pharma Group PLC, Church & Dwight Co. Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, OraCoat, Parnell Pharmaceuticals Inc., Pendopharm, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Synedgen among others. Key developments in Xerostomia (Dry Mouth Disease) Therapeutics Market include, in May 2018: Prisyna, the oral care division of Synedgen, received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn™ products designed to treat xerostomia.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population Base
    • 4.2.2 Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
    • 4.2.3 Increasing Prevalence of Diseases, such as Sjogren's syndrome, HIV, Diabetes, Alzheimer's disease, and Other Diseases
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness of Xerostomia in Developing and Underdeveloped Economies
    • 4.3.2 Unavailability of Effective Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product Type
    • 5.1.1 Artificial Saliva
    • 5.1.2 Salivary Stimulants
    • 5.1.3 Saliva Substitutes
    • 5.1.4 Drugs
    • 5.1.5 Salivary Pens
    • 5.1.6 Other Product Types
  • 5.2 Distribution Channel
    • 5.2.1 Hospital Pharmacy
    • 5.2.2 Retail Pharmacy
    • 5.2.3 Online Pharmacy
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Acacia Pharma
    • 6.1.2 Church & Dwight Co. Inc.
    • 6.1.3 GlaxoSmithKline PLC
    • 6.1.4 Hikma Pharmaceuticals PLC
    • 6.1.5 Lupin
    • 6.1.6 OraCoat
    • 6.1.7 Parnell Pharmaceuticals Inc.
    • 6.1.8 Pendopharm
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sun Pharmaceutical Industries Ltd
    • 6.1.11 Synedgen

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top